Serum Institute of India’s Vaccine to Treat Cervical Cancer Gets DCGI’s Nod, to Launch Later This Year

New Delhi, Jul 12: Serum Institute of India CEO Adar Poonawalla on Tuesday said the company plans to launch its indigenously-developed vaccine to treat cervical cancer in women later this year.

The Drugs Controller General of India (DCGI) on Tuesday granted market authorisation to Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer.

COVID-19: Serum Institute’s Coronavirus Vaccine Covovax Approved for Kids Aged 7 to 11 Years

In response to the approval by the drug regulator, Poonawalla in a tweet said, "For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the #DCGI @MoHFW_INDIA for granting approval today."

The approval by the drug regulator of SII's anti-cancer vaccine followed recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO on June 15.

Also Read | Maharashtra: Shiv Sena Urges Governor Bhagat Singh Koshyari To Avoid Eknath Shinde Cabinet Expansion.

The company had applied to the DCGI seeking market authorisation of the qHPV after the phase 2/3 clinical trial was completed with support of the Department of Biotechnology.

Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)